Agoracom Blog Home

Archive for the ‘ORTHO Regenerative Technologies’ Category

VIDEO – Ortho Regenerative $ORTH Closes $3M Financing & Agreement With Global Industry Leading Medical Company. CEO States “I Know We Are In The Lead”

Posted by Brittany McNabb at 11:50 AM on Thursday, April 7th, 2022

https://agoracom.com/ir/OrthoRegenerativeTechnologies

Have you ever torn a:

●       muscle

●       rotator cuff

●       meniscus

●       cartilage

How about someone you know? Or a favorite athlete?

We wouldn’t blame you if you thought the care and repair of these kinds of injuries is pretty standard and highly successful …. but you would be wrong.  There is a MASSIVE problem with surgery failure rates for each of these as follows:

●       Rotator Cuff   50-60%

●       Meniscus         20-40%

●       Cartilage         15-35%

$ORTH believes it has found the solution to this multi-billion dollar problem thanks to its proprietary RESTORE technology platform which dramatically improves the success rate of orthopedic and sports medicine surgeries.

In short, the technology uses biologics derived from things like plasma and bone marrow concentrate to regenerate new tissue in various musculoskeletal conditions.  This includes Wound Healing, Cartilage repair and Osteo-arthritis

In layman’s terms, it means $ORTH has a wonder delivery platform that delivers biologics – drugs made from biological processes – to repair soft tissues in the human body.

Newly appointed CEO Philippe Deschamps States “I Know We Are In The Lead” For FDA Trials Into The Healing Of Tendons, Ligaments, Cartilage and Meniscus .. and he has plenty of reason to carry such confidence considering the following …

3RD PARTY VALIDATION -$ORTH AGREEMENT WITH A GLOBAL STRATEGIC MEDICAL COMPANY FOR ITS ROTATOR CUFF TEAR REPAIR PHASE I/II U.S. CLINICAL TRIAL

On February 7th, $ORTH announced it entered into a Material Transfer Agreement (“MTA”) with an undisclosed, industry-leading, global strategic medical company for the exclusive use of their proprietary platelet-rich plasma (“PRP”) system in Ortho’s upcoming ORTHO-R rotator cuff tear (“RCT”) repair, phase I/II U.S. clinical trial.

The Strategic Company will provide the PRP system disposable kits for all enrolled patients in the study as well as technical and training support. $ORTH, in return, has provided the Strategic Company with a right of “first offer” to distribute ORTHO-R in combination with their proprietary PRP System.

$ORTH IS ATTACKING AND IN THE LEAD OF A MULTI BILLION $$ OPPORTUNITY

In terms of Soft Tissue Repair this is a massive market opportunity as follows:

ROTATOR CUFF TEAR – SHOULDER DYSFUNCTION AND PAIN

• 4m patients in the U.S. alone

• 600,000 annual surgeries in the U.S. alone

• $600m+ market opportunity

MENISCUS TEAR – PAINFUL AND COMPROMISES KNEE FUNCTION

• 1.2m surgeries annually in U.S. alone

• $1bn+ market opportunity

CARTILAGE LESIONS REPAIR – LESIONS CAUSE FRICTION AND PAIN

• 1.2m detected lesions annually in U.S. alone

• 120,000 surgeries and a lack of options

• $1bn+ market opportunity

Watch this powerful interview with CEO Philippe Deschamps

Ortho Regenerative Technologies $ORTH.ca $ORTIF Announces Submission of Investigational New Drug Application for ORTHO-R

Posted by AGORACOM at 9:30 AM on Tuesday, April 6th, 2021
Ortho
  • Phase I/II clinical trial initiation for rotator cuff tear repair in the U.S. anticipated in Q2 2021

MONTRÉAL, April 6, 2021  – Ortho Regenerative Technologies Inc . (CSE: ORTH) (OTC: ORTIF) (” Ortho RTI ” or the ” Company “), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, today announced that it has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for the initiation of a Phase I/II clinical trial of ORTHO-R in rotator cuff tear repair.

“The IND submission for our first ORTHO-R human trial is a key milestone for the Company. It brings us one step closer to the enrollment of our first patient, a recognized value creation event in our industry”, said Claude LeDuc , President and CEO of Ortho RTI.

“There is a clear need for improved rotator cuff tear repair treatments, as estimates have put the re-tear (or non healing) rate at an average of 50%. With more than 600,000 patients undergoing rotator cuff surgery every year in the U.S., this represents an enormous commercial opportunity, and as demonstrated in 2020 by our GLP preclinical program results, we strongly believe that ORTHO-R can help address these significant unmet needs and meaningfully improve the success rate of these surgeries.”

Read More: https://agoracom.com/ir/OrthoRegenerativeTechnologies/forums/discussion/topics/758565-ortho-regenerative-technologies-announces-submission-of-investigational-new-drug-application-for-ortho-r/messages/2310949#message

Ortho Regenerative Technologies $ORTH.ca $ORTIF Well-positioned for Next Phase of Development

Posted by AGORACOM at 3:43 PM on Tuesday, March 2nd, 2021
Ortho

MONTREAL , March 2, 2021 – Ortho Regenerative Technologies Inc . (CSE: ORTH) (OTCQB: ORTIF) (” Ortho RTI ” or the ” Company “), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, today provided a review of 2020 calendar year activities and a look forward at planned future milestones as the Company transitions from preclinical to clinical stage.

2020 Achievements

  • Completed four non-brokered private placements that raised an aggregate C$6.7 million . The company now has more than $2 million cash on hand to fund its regulatory and clinical stage projects through 2022.
  • In March and July, Ortho RTI announced positive preclinical results that confirmed the safety profile and demonstrated statistically significant improvement over standard of care for rotator cuff repair.
  • Following a request for designation to the FDA, ORTHO-R was classified in August as a drug/biologic, which management believes will enhance its long-term market potential.
  • In October, the Company appointed Mukesh Ahuja , MBBS, MSc as Vice-President Clinical and Medical Affairs, who brings extensive expertise in orthobiologics clinical development.
  • In October, Ortho RTI shares began trading on the OTCQB market, facilitating better access for US investors and improved trading liquidity.
  • In November, Ortho RTI initiated the scale-up and manufacturing of cGMP clinical trial material to be used in the upcoming ORTHO-R Phase I/II rotator cuff tear repair clinical trial in the US.

Read More: https://agoracom.com/ir/OrthoRegenerativeTechnologies/forums/discussion/topics/756371-ortho-regenerative-technologies-well-positioned-for-next-phase-of-development/messages/2306048#message

VIDEO – ORTHO Regenerative Technologies $ORTH.ca $ORTIF Is Preparing for The Big League, Appointing Patrick O’Donnell to Help Bring its Proprietary Surgery Tech to NASDAQ

Posted by AGORACOM-JC at 4:17 PM on Monday, March 1st, 2021
Ortho

Last week we introduced you to ORTHO Regenerative Technologies, a cutting-edge med tech firm that uses its proprietary RESTORE technology platform to dramatically improve the success rate of orthopedic and sports medicine surgeries.

  • In layman’s terms, that means company has a wonder delivery platform that delivers biologics – drugs made from biological processes – to repair soft tissues in the human body.

Now the firm has appointed Patrick O’Donnell to its board of directors.

  • O’Donnell comes with significant company-building experience
  • He will prove crucial in putting this healthcare pioneer on-track for a NASDAQ listing

Claude LeDuc, Ortho’s CEO, breaks down the appointment:

ORTHO REGENERATIVE TECHNOLOGIES $ORTH.ca $ORTIF ADDS PATRICK O’DONNELL TO BOARD OF DIRECTORS

Posted by AGORACOM at 11:40 AM on Thursday, February 25th, 2021
Ortho

Montreal, QC, February 24, 2021 – Ortho Regenerative Technologies Inc. (CSE: ORTH, OTCQB: ORTIF) (“Ortho RTI” or the “Company”), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today the appointment of Patrick O’Donnell to its Board of Directors, effective immediately. 

“We are very pleased to welcome Patrick to the Ortho RTI Board of Directors to help lead a very important transition in the development of our company, as we prepare to start our first U.S. multisite Ortho-R rotator cuff tear repair Phase I/II clinical trial”, said Claude LeDuc, President and Chief Executive Officer of Ortho RTI. “Ortho RTI will greatly benefit from Patrick’s company-building experience as well as his expertise in the development and management of strategic partnerships fund-raising, commercial, clinical, regulatory and reimbursement strategies, all specific to our industry. We are looking forward to his insightful contribution to our Board”. 

Commenting on his appointment to Ortho RTI’s Board of Directors, Mr. O’Donnell said: “I am happy to be joining the Board of Directors of Ortho RTI. The Company’s proprietary technology platform has the potential to help address significant unmet medical needs in a multitude of soft tissue repair related indications. I am excited to help Ortho RTI develop into an orthobiologics industry leader”. 

Read More: https://agoracom.com/ir/OrthoRegenerativeTechnologies/forums/discussion/topics/755959-ortho-regenerative-technologies-adds-patrick-o-donnell-to-board-of-directors/messages/2305098#message

VIDEO – ORTHO Regenerative Technologies $ORTH.ca $ORTIF is Using Proprietary Tech to Improve Surgery Success Rates and Seize a $5bn Market Opportunity

Posted by AGORACOM-JC at 7:17 PM on Sunday, February 21st, 2021

ORTHO Regenerative Technologies is a cutting-edge med tech firm that uses its proprietary RESTORE technology platform to dramatically improve the success rate of orthopedic and sports medicine surgeries.

  • In layman’s terms, that means company has a wonder delivery platform that delivers biologics – drugs made from biological processes – to repair soft tissues in the human body.

The technology uses biologics derived from things like plasma and bone marrow concentrate to regenerate new tissue in various musculoskeletal conditions.

  • This includes Wound Healing, Cartilage repair and Osteo-arthritis

So, how big is the market opportunity for Soft Tissue Repair? At least $5bn in the U.S. alone. This includes:

Rotator Cuff TEAR (which leads to shoulder dysfunction and pain):

  • 4m patients in the U.S. alone
  • 600,000 annual surgeries in the U.S. alone
  • $600m+ market opportunity

Meniscus Tear Repair (which is painful and compromises knee function):

  • There are 1.2m surgeries annually in U.S. alone
  • $1bn+ market opportunity

Cartilage Lesions Repair (this is where lesions cause friction and pain):

  • 1.2m detected lesions annually in U.S. alone
  • 120,000 surgeries and a lack of options
  • $1bn+ market opportunity

Get comfy for this insightful interview with Claude LeDuc, Ortho’s CEO.